Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

The global Psoriatic Arthritis (PsA) Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Being in remission is when there are no signs of active disease present. For some people with psoriatic arthritis, remission is possible with proper treatment. However, being in remission does not ...

should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous manifestations of psoriatic disease need to be considered in treatment targets.

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

HSS is the #1 orthopedic hospital in the world and a national leader in rheumatology. This content was created by our physicians and experts. Psoriatic arthritis a form of inflammatory arthritis that ...